公开(公告)号：US20240341291A1

公开(公告)日：2024-10-17

申请号：US18760465

申请日：2024-07-01

申请人： Regeneron Pharmaceuticals, Inc.

发明人： John MCWHIRTER ,  Cagan GURER ,  Lynn MACDONALD ,  Andrew J. MURPHY

IPC分类号： A01K67/0278 ,  C07K14/705 ,  C12N15/85 ,  G01N33/50

CPC分类号： A01K67/0278 ,  C07K14/70575 ,  C12N15/85 ,  G01N33/5088 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/07 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0325 ,  A01K2267/0381 ,  A01K2267/0387 ,  C07K2319/00 ,  G01N2500/10

摘要： Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.

公开(公告)号：US20240335538A1

公开(公告)日：2024-10-10

申请号：US18290668

申请日：2022-07-21

申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

发明人： Tae-Don KIM ,  Sooyun LEE

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783

CPC分类号： A61K39/464404 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4615 ,  A61K39/4631 ,  A61K39/464406 ,  A61K39/464411 ,  A61K39/464419 ,  A61K39/464429 ,  A61K39/464466 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70532 ,  C07K14/70535 ,  C07K14/7056 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/303 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

摘要： The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

公开(公告)号：US12103975B2

公开(公告)日：2024-10-01

申请号：US17217706

申请日：2021-03-30

申请人： Genentech, Inc.

发明人： Martin Gawlitzek ,  Shun Luo ,  Christina Teresa Bevilacqua

IPC分类号： C07K16/28 ,  C07K14/705 ,  C07K16/18 ,  C07K16/22 ,  C12N5/00

CPC分类号： C07K16/2878 ,  C07K14/70575 ,  C07K16/18 ,  C07K16/22 ,  C12N5/0018 ,  C12N5/0043 ,  C07K2317/14 ,  C07K2319/30 ,  C12N2500/32 ,  C12N2500/33 ,  C12N2500/90

摘要： The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.

公开(公告)号：US20240299451A1

公开(公告)日：2024-09-12

申请号：US18441467

申请日：2024-02-14

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： Reshmi Parameswaran

IPC分类号： A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K38/177 ,  A61K38/1774 ,  A61K45/06 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K16/2803 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

摘要： The disclosure relates generally to ligand-based chimeric antigen receptor (CAR) cells. More specifically, the CAR cells express B-cell activating factor (BAFF) protein for recognition by a receptor of BAFF on the surface of a cell. CAR cells can include cytotoxic T lymphocytes, natural killer (NK) cells or natural killer T (NKT) cells that express a chimeric receptor that recognizes a receptor of BAFF. The disclosure further relates to methods of treating a variety of conditions, such as cancers and autoimmune diseases, using the disclosed CAR cells.

公开(公告)号：US20240279336A1

公开(公告)日：2024-08-22

申请号：US18291271

申请日：2022-07-29

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  NANTES UNIVERSITÉ

发明人： Nicolas BOISGERAULT ,  Tacien PETITHOMME

IPC分类号： C07K16/28 ,  A61K38/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/30 ,  C12N15/86

CPC分类号： C07K16/2827 ,  A61P35/00 ,  C07K14/70575 ,  C07K16/2818 ,  C07K16/30 ,  C12N15/86 ,  A61K38/00 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2760/20243

摘要： Chimeric proteins for cancer immunotherapy can combine different activities by displaying both agonistic and antagonistic properties on a single molecule. However, those usually exhibit toxicities related to their potency being exerted in the entire organism and not only in tissues relevant for cancer treatment. This may be solved by using appropriate vectorization of the chimeric proteins to the tumour microenvironment, where immune cells interact with tumour cells expressing immunomodulatory molecules. The present invention relates to a nucleic acid encoding a chimeric protein or a chimeric protein having a general structure of: N terminus-(a)-(b)-(c)-C terminus, wherein: (a) is a signaling and/or targeting domain. (b) is a linker (b) is a functional linker and (c) is a signaling and/or targeting domain or N terminus-(c)-(b)-(a)-C terminus, wherein: (c) is a signaling and/or targeting domain. (b) is a linker (b) is a functional linker and (a) is a signaling and/or targeting domain.

公开(公告)号：US12055549B2

公开(公告)日：2024-08-06

申请号：US17325036

申请日：2021-05-19

申请人： UCB Biopharma SRL ,  SANOFI

发明人： James Philip O'Connell ,  John Robert Porter ,  Alastair Lawson ,  Tracy Lynn Arakaki ,  Daniel John Lightwood ,  Rebecca Jayne Munro

IPC分类号： G01N33/68 ,  A61K47/64 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/705 ,  C07K16/24

CPC分类号： G01N33/6845 ,  A61K47/6425 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/70575 ,  C07K16/241 ,  G01N33/6854 ,  G01N33/6863 ,  C07K2317/55 ,  C07K2317/92 ,  G01N2333/525 ,  G01N2500/02

摘要： It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

公开(公告)号：US20240252732A1

公开(公告)日：2024-08-01

申请号：US18607187

申请日：2024-03-15

申请人： IMMUNICOM, INC.

发明人： Michael MATHO ,  Steven F. JOSEPHS ,  Annette MARLEAU

IPC分类号： A61M1/36 ,  A61K39/395 ,  A61M1/34 ,  B01D15/38 ,  C07K14/525 ,  C07K14/555 ,  C07K14/705 ,  G01N33/543

CPC分类号： A61M1/362 ,  A61K39/395 ,  A61K39/39516 ,  A61K39/39525 ,  B01D15/3809 ,  B01D15/3828 ,  C07K14/525 ,  C07K14/555 ,  C07K14/70575 ,  G01N33/543 ,  G01N33/54353 ,  A61M1/3496

摘要： A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.

公开(公告)号：US20240139248A1

公开(公告)日：2024-05-02

申请号：US18409191

申请日：2024-01-10

申请人： Noile-Immune Biotech, Inc.

发明人： Koji TAMADA ,  Yukimi SAKODA ,  Keishi ADACHI

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C12N15/63

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/521 ,  C07K14/5418 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70575 ,  C12N15/63 ,  A61K38/00

摘要： An object of the present invention is to provide an immunocompetent cell targeting mesothelin. An immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, interleukin 7 (IL-7), and chemokine (C-C motif) ligand 19 (CCL19) is produced. It is preferred that: the cell surface molecule specifically recognizing human mesothelin should be chimeric antigen receptor (CAR) having single chain antibody, a transmembrane region, and a signaling region that induces the activation of the immunocompetent cell; and the heavy chain variable region and the light chain variable region should be connected via a peptide linker consisting of a 2- to 30-amino acid sequence.

公开(公告)号：US11952411B2

公开(公告)日：2024-04-09

申请号：US17405872

申请日：2021-08-18

申请人： JANSSEN BIOTECH, INC.

发明人： Adam Zwolak ,  Szeman Chan ,  Rajkumar Ganesan

IPC分类号： C07K14/705 ,  A61K38/00 ,  A61P37/04 ,  C07K14/765

CPC分类号： C07K14/70575 ,  A61P37/04 ,  C07K14/765 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/74

摘要： Described herein are compositions and kits that comprise an engineered TL1A ligand that displays high stability, minimal binding to decoy receptor DcR3 while retaining functional activity via binding to its cell surface receptor, DR3, and the ability to activate T cells in vitro and in vivo. Methods of making an engineered TL1A ligand and methods of treating a disease or disorder in a subject by administering an engineered TL1A ligand are also provided.

公开(公告)号：US11879017B2

公开(公告)日：2024-01-23

申请号：US17410129

申请日：2021-08-24

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services

发明人： Richard A Morgan ,  Steven A. Rosenberg

IPC分类号： C07K16/32 ,  G01N33/574 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  A61K39/00 ,  C07K16/28 ,  A61K48/00 ,  A61K38/00

CPC分类号： C07K16/32 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70503 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/2863 ,  C07K16/3053 ,  G01N33/57492 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K2317/21 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/70 ,  G01N2333/71

摘要： The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.